has announced an MoU to supply its lead compound SFX-01 towards a clinical trial in patients diagnosed with Autism Spectrum Disorder (ASD). The trial is sponsored by Guy's and St Thomas' NHS Foundation Trust and will be conducted at the Evelina London Children’s Hospital.
Once Evgen has supplied the drug, the Trust will lead the process to secure grant funds and gain clinical trial approval. At the end of the trial, Evgen has retained the option to acquire the clinical data spur any subsequent development and commercialisation.
The trial’s aim is to provide clarity over whether the components of SFX-01 could be geared for treating ASD.
SFX-01 contains a “stabilised synthetic sulforaphane molecule,” a variant of which has shown to have “potential” in the treatment of ASD in a few small clinical trials in the US.
Currently, there are no approved medicines for treating thee three core symptoms of autism, “communication difficulties, social challenges and repetitive behaviour.”
Should the SFX-01 compound prove to be useful in the treatment of ASD, it would be a significant breakthrough for the disorder and disrupt a £3bn ASD market typically focused on drugs such as antidepressants meant to treat non-core symptoms.
For more news and updates on Evgen Pharma:
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
Next is ‘weathering the retail storm’ as it enjoyed a rise in half-year profits, the store’s boss revealed, The competition watchdog said JD Sports £90m takeover of Footasylum could lead to “higher prices” and “worse choice” for shoppers, but fell short of explaining its reasons in more detail
Travel firm Thomas Cook has been hit with a last-minute demand, from its banks, to find £200m in extra funding in order to secure its future. The troubled operator hoped to seal a rescue deal this week but without this, the firm is likely to collapse.
Salt Lake Potash explain the significance of producing premium grade water soluble sulphate Of potash from its Lake Way Project. Iconic Labs discuss their strategy and recent deals. Chris Bailey on Next, Diageo & Johnson Matthey. John Meyer on Kodal Minerals, Arc Minerals & BlueJay Mining.
SP Angel research note on commodities and miners, featuring: Asiamet Resources (ARS LN) - Logistics enhancements Bushveld Minerals* (BMN LN) BUY – Valuation 92p – Conference presentation in South Africa highlights forecast growth of vanadium electrolyte demand Kodal Minerals* (KOD LN) - ESIA Progress Report IronRidge Resources* (IRR LN) - Aircore results from Cote d'Ivoire Ironveld (IRON LN) – NED director resignation Solgold* (SOLG LN) - Constitutional Court ruling in Ecuador
The main trade union at Royal Mail has served notice for a strike ballot among 110,000 workers, Hong Kong is under growing pressure to sweeten the terms of its £32bn offer for the London Stock Exchange Group as a takeover battle for the British bourse intensifies
The US central bank has cut interest rates for only the second time since 2008, amid concerns about slowing global growth and trade wars. As expected the Federal Reserve lowered the target range for its key interest rate by 25 basis points to between 1.75% and 2%.